In addition to angiogenesis inhibitors, rapamycin (mTOR) targeted inhibitors, and immune checkpoint inhibitors have been also approved by the Food and Drug Administration for the first-line treatment of patients with advanced ccRCC (85, 86). Here, MTOR is linked to nonpapillary renal cell carcinoma.